Strategic Shift Toward Complex Generics and Innovative Medicines
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
-
Performance was driven by strong demand in North America and Greater China, specifically for cardiovascular portfolios and established brands.
-
North America growth is accelerating as the portfolio mix shifts toward durable, higher-margin products and complex generics, such as estradiol patches and new injectables.
-
Greater China growth was supported by e-commerce uptake but moderated by the implementation of hospital-focused procurement policy changes.
-
Supply constraints at the Nashik facility, resulting from remediation activities, created a $100 million revenue headwind in Europe and emerging markets during the quarter.
-
The proposed acquisition of Pacira BioSciences is intended to add two established patent-protected medicines, EXPAREL and ZILRETTA, to the U.S. Promoted Brands business.
-
Management is leveraging global infrastructure to transition the business toward innovative medicines, expecting the U.S. innovative segment to exceed $1 billion in revenue by 2027.
Pipeline Milestones and Integration Outlook
-
Raised 2026 financial guidance assumes continued momentum in the U.S. and increasing supply for estradiol patch products, partially offset by new competition.
-
The FDA review for fast-acting meloxicam is substantially complete, with a PDUFA date of December 27 and an anticipated launch in early 2027.
-
Phase III data readouts for blockbuster potential candidates selatogrel and cenerimod are expected in the first half of 2027.
-
The Pacira transaction is expected to be immediately accretive to all 2027 financial metrics, with projected annual cost synergies of at least $50 million by the end of 2028.
-
Japan is positioned for a return to growth driven by the expected launch of Wakix and continued uptake of Effexor and Spydia.
Operational Risks and Structural Changes
-
The Nashik facility received an Official Action Indicated (OAI) classification from the FDA, leading to a precautionary suspension of manufacturing while remediation is ongoing.
-
The acquisition of Pacira BioSciences will be funded through excess cash and short-term borrowings, maintaining a gross leverage ratio near the 2.9x level.
-
Paul Duffy has been appointed as the new Chief Supply Officer following the retirement of Peter McCormick after 30 years with the company.
Q&A Session Insights
Impact of China hospital procurement policy changes
-
Growth moderated from 16-17% in the first half to 10% in Q3 as policy enforcement varied across different provinces.
-
Management expects Q4 growth to be lower than Q3 as more provinces implement the policy, with 2027 growth returning to low-to-mid single digits.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
EBITDA growth trajectory and 2030 financial targets
-
Management indicated that current business momentum and Pacira synergies could bring long-term EBITDA targets within reach earlier than the original 2030 timeline.
-
Specific 2027 guidance will be withheld until the end of the current fiscal year.
EXPAREL generic competition and life cycle management
-
Viatris expects continued growth for EXPAREL until a volume-limited generic entry in 2030.
-
The company plans to use its intellectual property expertise to defend the portfolio and sustain meaningful sales even after generic entry.
Drivers of increased demand for estradiol patches
-
Demand is surging due to the removal of FDA black box warnings and the rise of GLP-1 usage, which makes transdermal delivery more favorable due to delayed gastric emptying.
-
Viatris is expanding manufacturing capacity, moving to 24/7 operations and adding packaging lines to meet an estimated 1 million additional users in 2027.
Cenerimod Phase III study design and interferon signature
-
A pooled analysis for the interferon-1-high signature group is prespecified in the statistical analysis plan to ensure sufficient power for steroid-sparing endpoints.
-
Management noted that different gene signature panels lead to similar results in identifying high-risk responders.
